The following is a summary of “Neoadjuvant Pembrolizumab in Stage I-III Deficient Mismatch Repair Colon Cancer: A Clinical ...

Pembrolizumab plus radiotherapy and surgery significantly improved disease-free survival. 2. Grade 3 or higher adverse events ...

Teos Therapeutics has potential lung cancer treatment despite issues and strong financial position. Read here to know why we ...

In this randomized controlled trial, among patients with early-stage triple-negative breast cancer (TNBC), the addition of ...

The findings, published in The Lancet, establish pembrolizumab as a new option for patients with this disease. "Soft tissue sarcoma is a rare and complex disease with over 50 different subtypes ...

Merck halts vibostolimab and favezelimab trials due to efficacy results, prioritizing its oncology pipeline while the FDA ...

Oncologists want definitive guidance on whether patients with resectable NSCLC benefit from immunotherapy before and after ...

Conventional radiation treatment might slow their growth, but Carter was certain to die. Then his doctors gave him pembrolizumab (Keytruda), a new immunotherapy medication that could spur a patient’s ...

New research revealed tumor mutational burden was linked to improved event-free survival with pembrolizumab in early TNBC, ...

However, results from the randomized KEYNOTE-522 study showed an improvement in overall survival (OS) in patients with stage II-III TNBC who received pembrolizumab (Keytruda) before and after ...

Pembrolizumab plus fulvestrant provided disease control in 50% of patients with ER-positive, HER2-negative metastatic breast cancer.

Josep M. Llovet, MD, PhD, describes the phase 3 LEAP-012 clinical study, including its methods, design, and enrollment ...